In late April 2026, the Department of Justice and DEA, acting under President Trump's December 2025 executive order, issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, effective April 28—marking a partial federal shift that eases research and tax burdens for medical operators while recreational marijuana remains Schedule I. This development, withdrawing prior proceedings for efficiency, has driven trader sentiment by fulfilling some reform expectations but delaying full rescheduling, with an expedited administrative hearing set to begin June 29 at DEA headquarters and conclude by mid-July, potentially yielding a final rule shortly after. Outcomes hinge on hearing evidence, legal challenges, and agency timelines amid ongoing state-federal tensions.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour$758,300 Vol.
31 mars 2026
30 juin
2%
31 décembre
25%
$758,300 Vol.
30 juin
$336,927 Vol.
2%
31 décembre
$156,491 Vol.
25%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.In late April 2026, the Department of Justice and DEA, acting under President Trump's December 2025 executive order, issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, effective April 28—marking a partial federal shift that eases research and tax burdens for medical operators while recreational marijuana remains Schedule I. This development, withdrawing prior proceedings for efficiency, has driven trader sentiment by fulfilling some reform expectations but delaying full rescheduling, with an expedited administrative hearing set to begin June 29 at DEA headquarters and conclude by mid-July, potentially yielding a final rule shortly after. Outcomes hinge on hearing evidence, legal challenges, and agency timelines amid ongoing state-federal tensions.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Marché ouvert : Feb 7, 2026, 5:04 PM ET
Volume
$758,300Date de fin
31 mars 2026Marché ouvert
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.In late April 2026, the Department of Justice and DEA, acting under President Trump's December 2025 executive order, issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, effective April 28—marking a partial federal shift that eases research and tax burdens for medical operators while recreational marijuana remains Schedule I. This development, withdrawing prior proceedings for efficiency, has driven trader sentiment by fulfilling some reform expectations but delaying full rescheduling, with an expedited administrative hearing set to begin June 29 at DEA headquarters and conclude by mid-July, potentially yielding a final rule shortly after. Outcomes hinge on hearing evidence, legal challenges, and agency timelines amid ongoing state-federal tensions.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$758,300Date de fin
31 mars 2026Marché ouvert
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...In late April 2026, the Department of Justice and DEA, acting under President Trump's December 2025 executive order, issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, effective April 28—marking a partial federal shift that eases research and tax burdens for medical operators while recreational marijuana remains Schedule I. This development, withdrawing prior proceedings for efficiency, has driven trader sentiment by fulfilling some reform expectations but delaying full rescheduling, with an expedited administrative hearing set to begin June 29 at DEA headquarters and conclude by mid-July, potentially yielding a final rule shortly after. Outcomes hinge on hearing evidence, legal challenges, and agency timelines amid ongoing state-federal tensions.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes